%PDF-1.4
%
267 0 obj
<>
endobj
257 0 obj
<>
endobj
256 0 obj
<>stream
Arbortext Advanced Print Publisher 10.0.1465/W Unicode
2024-03-28T18:48:50-07:00
2017-02-17T10:52:38+05:30
2024-03-28T18:48:50-07:00
application/pdf
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
Acrobat Distiller 8.1.0 (Windows)
uuid:3763ae9e-eead-49bf-b148-48204c36ac08
uuid:290b8ad3-1dd2-11b2-0a00-1e00085ab1ff
endstream
endobj
268 0 obj
<>
endobj
175 0 obj
<>
endobj
253 0 obj
<>
endobj
255 0 obj
<>
endobj
5 0 obj
<>
endobj
156 0 obj
<>
endobj
152 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 153 0 R/Type/Page>>
endobj
359 0 obj
<>stream
HWn9}WQ"k8ĝ
J-UwbI ]=?W^].-_%^em,%JGe\'B*^8-jصBJ{l~BH%^0΅
㳼7ugj凞]"
7)@Cz˿BgyO)O%J5x܀Njb/m(/VI2nj.}5
nf[$x{l^lLΐfC`ߏXzxQ)`p/
Vw#g|;QHK Ii_elf&l[4~kMRLAp~c>(ppWV;lkwfr{WrXSHSE瑻B술2817xQrg81
\֦U9ڃ,*$(VM,سYT wM1~;W>bhE@i1-K}/ 9NCt*)o*
݃!ͯC'&
{-G8(׆+)`xӾig
6=
b uYԶQ=WRiCg_U IXڎlɛ ~o6|Slw6XJU[t߹љ
R(VYoa ko\ZH'\r pH#Z/i$K3.%8lB/P1JPVqI#KԄWe{EMr
Cۮ8t@` E0E*CS}.t*P[1uYmO3H`0q@
a 72/©(
xrǘ,Ԍ"[5u.%»r)f(}nM-(s~߂w]UA.le];;ÅJiXPL~wY~.Dۛ`|B?/.}@U3iv{~fE|$gO~N[읤 g_4[9@݂ $]EYyNXŃ`;+3z
: +jʵk8A 39>jDLDw]teXXL1f>
yQxg߹!c<wǃ9%̩ԲDDثRĘ&rFlFh1/%O'? W9&u%7t.$d~fh6)O`Fp0
bFG92%9@ޗJZZ`=RNߧKj~#ϥ^Ia**rm;rj+eCd(6_pa <a&